What is thymosin alpha 1?
A short peptide from thymus biology, a synthetic counterpart called thymalfasin, and several similar names that refer to different molecules.
Thymosin alpha 1 peptide
Thymosin Alpha-1 is a 28-amino-acid peptide associated with immune regulation. In 1977, Goldstein and colleagues purified it from calf thymus and determined its sequence. It came from thymosin fraction 5, a preparation containing multiple thymic components. The purified molecule gave that mixture a much more definite identity.
The body releases the peptide from a larger precursor, prothymosin alpha. Thymalfasin is the synthetic, sequence-identical form used in the clinical literature described by the comprehensive review. The natural origin and the manufactured medicine explain why a paper may discuss a substance already present in the body and then describe administering it as a drug.
The achievement I admire here is the move from an extract to an identifiable molecule. A mixture and an identified molecule allow different experiments. Once the sequence was known, investigators could ask about the same peptide rather than a changing collection of extracts.
TA1 meaning and thymalfasin
TA1, Tα1 and thymosin alpha 1 are names for the peptide discussed here. Thymalfasin names its synthetic counterpart. The clinical review of thymosin alpha 1 brings the manufacturing and medical literature together.
The shared “thymosin” root is less precise. Thymosin beta-4, thymulin and thymopentin have their own identities. A claim becomes hard to follow when the full molecule name disappears midway through it.
Dendritic-cell signalling
Dendritic cells present material to T cells and help shape the response that follows. The 2006 work on dendritic-cell tryptophan metabolism combined experiments in mouse and human cells with mouse experiments. It connected Thymosin Alpha-1 with Th1 immune priming and with IDO-dependent regulatory activity.
The regulatory side matters to the new-cell question. An immune population also needs instructions about how strongly to respond. I prefer the biological messiness of recruitment and restraint to a single upward dial. The cell and animal findings leave human treatment effects to clinical trials.
In a separate human blood-cell model exposed to SARS-CoV-2 stimulation, Thymosin Alpha-1 reduced TNF-α, IL-6 and IL-8 while increasing IL-10. Those were laboratory results from cells outside the body. The experiment measured inflammatory signalling; survival and recovery require studies of people.
Thymosin alpha 1 vs thymosin beta 4
Thymosin Alpha-1 has 28 amino acids; thymosin beta-4 has 43. TB-500 is associated with the beta-4 family and tissue-repair research. The alpha peptide discussed in the original sequence paper has a different sequence and research history.
Thymulin is a zinc-dependent peptide with nine amino acids. Thymopentin, also called TP-5, has five. Thymalin is a mixture of thymic components, while prothymosin alpha is the larger precursor from which Thymosin Alpha-1 is released. Those distinctions are described in the research reading list and the clinical review.
Calling every one of these molecules “thymosin” tests my patience. A full name is a small courtesy that saves a great deal of confusion.
Clinical uses and approval
Clinical studies have investigated thymalfasin in viral hepatitis, HIV, sepsis, vaccination, transplantation and cancer combinations. The broad review describes approval abroad, while Thymosin Alpha-1 has no FDA approval in the United States.
The HIV studies explain the interest in immune reconstitution. The benefits survey follows the disease outcomes, including the negative sepsis result. Research on muscle growth or strength is absent from the clinical evidence collected here.